'We expect the above factors to continue through the summer,' says Merrill Lynch. The concern over an official probe into sales practices at US group Bristol-Myers Squibb provides an uphelpful backdrop to the sector. So, too, is the increasingly aggressive line taken by governments on the pricing of drugs.